Key result
Imeglimin administration for 3 months significantly improved 2-hour postprandial flow-mediated dilation from a median of 2.3 to 2.9 (p=0.013) in patients with type 2 diabetes.
Why the study?
Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes, leading to the hypothesis that imeglimin would improve endothelial function.
Does imeglimin improve endothelial function in patients with type 2 diabetes?
Observational (n=12)
No
Does imeglimin improve endothelial function in patients with type 2 diabetes?
Absolute Event Rate: 2.9% vs 2.3%
p-value: p=0.013
Imeglimin administration for 3 months significantly improved 2-hour postprandial flow-mediated dilation and glycemic control in patients with type 2 diabetes.
May support endothelial benefits of imeglimin in type 2 diabetes; leaves open confirmation in randomized trials.
INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and HbA1c ≥ 6.5% who were not receiving insulin therapy. A meal tolerance test (592 kcal, glucose 75.0 g, fat 28.5 g) was performed before and 3 months after administration, and endothelial function, blood glucose, insulin, glucagon, and triglycerides were evaluated. Endothelial function was assessed by flow-mediated dilation (FMD). RESULTS: Twelve patients (50% male) with a median age of 55.5 years old (interquartile range [IQR] 51.3-66.0) were enrolled. Fasting FMD did not differ before or 3 months after imeglimin administration (from 6.1 [3.9-8.5] to 6.6 [3.9-9.0], p = 0.092), but 2 h postprandial FMD was significantly improved 3 months after imeglimin administration (from 2.3 [1.9-3.4] to 2.9 [2.4-4.7], p = 0.013). In terms of the glucose profile, imeglimin administration significantly improved HbA1c (from 7.2 ± 0.6% to 6.9 ± 0.6%, p = 0.007), fasting glucose (from 138 ± 19 mg/dL to 128 ± 20 mg/dL, p = 0.020), and 2 h postprandial glucose (from 251 ± 47 mg/dL to 215 ± 68 mg/dL, p = 0.035). The change in 2 h postprandial FMD between before and 3 months after imeglimin administration (Δ2 h postprandial FMD) was negatively correlated with Δ2 h postprandial glucose (r = - 0.653, p = 0.021) in a univariate correlation coefficient analysis. Both patients with and without decreased postprandial glucose 3 months after imeglimin administration had improved postprandial FMD. CONCLUSION: In this small study, imeglimin administration improved 2 h postprandial FMD. Both glycemic control-dependent and -independent mechanisms might contribute to improved endothelial function. TRIAL REGISTRATION: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000046311).
No takes yet. Share an insight, caveat, or question.
Uchida et al. (2023) conducted an observational in Type 2 diabetes (n=12). Imeglimin vs. Baseline (before administration) was evaluated on Change in 2 h postprandial flow-mediated dilation (FMD) (p=0.013). Imeglimin administration for 3 months significantly improved 2-hour postprandial flow-mediated dilation from a median of 2.3 to 2.9 (p=0.013) in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: